Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | CCR2 | P41597 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | PTPRC | P08575 | 1/20 | 0.31 |
| ▸ | PTPRF | P10586 | 1/20 | 0.31 |
| ▸ | CDC25B | P30305 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL900953 | 0.91 | MAPT (0.70) | MAPTMAOAMAOBHIF1ACCR2 | |
| SCHEMBL2569326 | 0.88 | MAPT (0.51) | MAPTMAOAMAOBHIF1APTPN1 | |
| SCHEMBL1237586 | 0.87 | MAPT (0.70) | MAPTMAOAMAOBHIF1ACCR2 | |
| SCHEMBL1235852 | 0.85 | MAPT (0.68) | MAPTMAOAMAOBHIF1ACCR2 | |
| SCHEMBL3397911 | 0.85 | MAPT (0.62) | MAPTMAOAMAOBHIF1ACCR2 | |
| SCHEMBL1021060 | 0.84 | MAPT (0.56) | MAPTMAOAMAOBHIF1ACCR2 | |
| SCHEMBL1238056 | 0.83 | MAPT (0.55) | MAPTMAOAMAOBHIF1ACCR2 | |
| SCHEMBL11181983 | 0.83 | MAPT (0.65) | MAPTMAOAMAOBHIF1ACCR2 | |
| SCHEMBL14763707 | 0.76 | MAPT (0.57) | MAPTHIF1ACCR2 | |
| SCHEMBL2205029 | 0.74 | MAPT (0.64) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9499558-B2 | Compounds and methods for treating HIV | PURDUE RESEARCH FOUNDATION (US) | 2016-11-22 | — | — | US | disclosed |
| US-20150225414-A1 | COMPOUNDS AND METHODS FOR TREATING HIV | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-08-13 | — | — | US | disclosed |
| US-9024038-B2 | Compunds and methods for treating HIV | PURDUE RESEARCH FOUNDATION (US) | 2015-05-05 | — | — | US | disclosed |
| EP-2768307-A1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | Bikam Pharmaceuticals, Inc. (US) | 2014-08-27 | — | — | EP | disclosed |
| US-20130289067-A1 | COMPOUNDS AND METHODS FOR TREATING HIV | PURDUE RESEARCH FOUNDATION | 2013-10-31 | — | — | US | disclosed |
| WO-2013058809-A1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | BIKAM PHARMACEUTICALS, INC. (US) | 2013-04-25 | — | — | WO | disclosed |
| WO-2012092168-A1 | FUSED 6,5 BICYCLIC RING SYSTEM P2 LIGANDS, AND METHODS FOR TREATING HIV | PURDUE RESEARCH FOUNDATION (US) | 2012-07-05 | — | — | WO | disclosed |
| WO-2010016552-A1 | THERAPEUTIC AGENT FOR IRRITABLE BOWEL SYNDROME | 武田薬品工業株式会社 (JP) | 2010-02-11 | — | — | WO | disclosed |
| EP-1404690-A1 | NOVEL MULTINUCLEAR HALF METALLOCENE CATALYST AND PREPARATION OF STYRENE POLYMER USING THE SAME | LG Chem, Ltd. (KR) | 2004-04-07 | — | — | EP | disclosed |
| WO-2003006473-A1 | NOVEL MULTINUCLEAR HALF METALLOCENE CATALYST AND PREPARATION OF STYRENE POLYMER USING THE SAME | LG CHEM, LTD. (KR) | 2003-01-23 | — | — | WO | disclosed |
| US-5929087-A | Decahydroquinoline-based anti-cholinergic agents | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1999-07-27 | — | — | US | disclosed |
| US-5137869-A | Methyl substituted tetrahydroindanone and perfumery uses thereof | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 1992-08-11 | — | — | US | disclosed |
| US-5137869-A | Methyl substituted tetrahydroindanone and perfumery uses thereof | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 1992-08-11 | — | — | US | disclosed |
| US-5137869-A | Methyl substituted tetrahydroindanone and perfumery uses thereof | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 1992-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225414-A1 | COMPOUNDS AND METHODS FOR TREATING HIV | SERPINB1, HPN, DNPEP | MAPT 1037/4885MAOA 512/4885MAOB 386/4885 |
| US-20130289067-A1 | COMPOUNDS AND METHODS FOR TREATING HIV | SERPINB1, HPN, DNPEP | MAPT 1037/4885MAOA 512/4885MAOB 386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.